Gavi Alliance Audit and Finance Committee Meeting
17 July 2025
Virtual Meeting

1. Chair's report

1.1 Noting that the meeting had been duly convened and finding a quorum of members present, the meeting commenced at 14.01 Geneva time on 17 July. Mr David Sidwell, AFC Chair, chaired the meeting.

1.2 Standing declarations of interest were tabled to the Committee (Doc 01a in the Committee pack).

1.3 The Chair acknowledged the strong attendance at the technical briefing held on 16 July 2025 and emphasised that this meeting should serve as a forum for discussion and to provide strategic guidance to the Gavi Secretariat. He stressed the need to clarify the updated resource range, review the US$ 13 billion unconstrained cost estimate (to serve as Gavi 6.0 recalibration baseline), and explore financial levers, risks, and opportunities to help the Secretariat prepare for the upcoming Board Retreat.

1.4 The Chair also stressed the importance of breaking down routine versus campaign costs, understanding cash flow reclassifications and commitments across strategic periods, and ensuring confidence in the cash carry-forward to support the delivery of Gavi's mission.

2. CEO update

2.1 Sania Nishtar, CEO, Gavi noted that despite the volatile global context, 2024 showed strong performance, including record co-financing contributions from Gavi-supported countries and emergency vaccination efforts that averted over 320,000 deaths and yielded US$ 32 billion in economic benefits.

2.2 She highlighted the outcome of the Global Health Summit held on 23 June 2025, noting that while US$ 9 billion was raised, the target of US$ 11.9 billion remains unmet. She emphasised that this shortfall necessitates a recalibration of the Gavi 6.0 strategy and stressed that the decision making will rest with the Gavi Board.

2.3 Finally, she noted that following the Gavi Board meeting in July 2025, the Audit and Finance Committee (AFC) will meet in October to revise and formalise the Gavi 6.0 forecast. This will be followed by a meeting of the Programme and Policy Committee (PPC) to update the Gavi 6.0 sub-strategies and approaches in line with recalibrated priorities.

Discussion

- With the Committee's agreement, the Chair proposed that any questions or comments on Dr Nishtar's presentation be held until after the discussion of agenda item three.

------

3. Financial Resource Implications of Replenishment and Gavi 6.0 resources

3.1 François Note, Chief Financial Officer, provided an overview of resources, risks and opportunities and financial instruments. He confirmed US $9 billion in secured funding following the Global Summit and the updated recalibration range of US$ 10-10.5 billion, with the ambition to reach the original $11.9 billion target over the Gavi 6.0 strategic period.

3.2 He noted that the Gavi 6.0 strategic cost estimate (US$ 11.9 billion approved by the Gavi Board in June 2024) has been updated to US$ 13.0 billion to reflect recommendations from the PPC to the Board, and external factors. He stated that this amount will form the base for recalibration and therefore the US$ 2.5 - 3 billion funding gap will be addressed at the upcoming Board Retreat.

3.3 Mr Note broke down the composition of the US$ 9 billion of secured funding, noting that ring-fenced financing instruments and reserves totalled US$ 3.2 billion and are not included in the recalibration figures. Finally, he presented a risk-based methodology used to define the lower and upper recalibration targets.

3.4 Ian MacTavish, Director, Finance & Chief Accounting Officer, discussed multi-year commitments to countries and emphasised the importance of routine programmes, campaign vaccines, and outbreak responses. He detailed the costs associated with various vaccine programmes, and introduced the Consolidated Cash Envelope, which includes Health System Strengthening (HSS) programming, campaign support, and country technical assistance. He also highlighted the fragile and humanitarian approach, market shaping efforts, and the importance of achieving cost savings to ensure the financial sustainability of vaccine programmes.

3.5 Additionally, he explained the approach to managing financial commitments and risks, including the use of financial instruments such as the First Response Fund (FRF). He stressed the importance of maintaining flexibility in financial planning and highlighted the importance of ongoing evaluation and adjustment to ensure the organisation can meet its goals and respond to changing circumstances.

3.6 Johannes Ahrendts, Director, Strategy Design & Delivery, discussed the proposed methodology for recalibration, which includes 12 levers structured around Gavi's four strategic goals and a fifth category for partner and Secretariat support. He noted that each lever provides cost-reduction options for the Board's consideration to ensure that Gavi can meet its goals and respond to changing circumstances.

Discussion

- The Secretariat clarified that the US$ 10 billion figure is the best estimate, with the target remaining at US$ 11.9 billion. They agreed to retain the recalibration range from US$ 9.5 billion to US$ 10.5 billion, allowing for flexibility while acknowledging uncertainties in donor commitments.
- Regarding whether the risk of delayed contributions has been factored into interest income projections, the Secretariat confirmed that it used a conservative interest rate assumption and will revisit this in October 2025.
- On the topic of Pandemic Vaccine Programmes (PVP), the Secretariat clarified that out of the US$ 1.9 billion in PVP, US$ 1.4 billion has been confirmed and stated that the remaining US$ 500 million is under negotiation with a select group of donors.
- Addressing the gap between IFFIm pledges and the investment case target, the Secretariat noted that the World Bank's current forecast assumes a closedown scenario due to pending pledges and that the forecast will be updated to reflect expected contributions.
- Regarding whether Multilateral Development Bank (MDB) funds can support the Secretariat's HSS programming, the Secretariat responded that while credit lines cannot be substituted, they can be leveraged to accelerate country-level impact.
- On interest allocations from the African Vaccine Manufacturer Accelerator (AVMA) and First Response Fund (FRF), the Secretariat expressed confidence in ongoing donor discussions and stated that if repurposing is not confirmed by the end of 2025, it will reassess the situation.
- On the implications if countries are unable to repurpose COVAX funds before the end of 2025, the Secretariat noted that negotiations with the affected countries are ongoing.
- The Secretariat clarified that any unused 2025 cash would be considered part of Gavi 6.0 funding.
- Regarding procurement fees, the Chair and Secretariat acknowledged that adjustments in vaccine volumes should reflect in procurement costs.
- On how partner funds are allocated, the Secretariat acknowledged the need for more transparency and committed to providing a breakdown of partner funding components. The Secretariat also expressed support for joint workforce planning across the Gavi Alliance to ensure efficiency.
- Addressing risk, the Secretariat emphasised that about US$ 100 million of existing programmes are subject to rescoping, and that most changes focus on

new activities. It acknowledged the importance of careful communication to manage expectations and reputational impact.

- On the vaccine cost risk assessment, the Secretariat explained that the 10% variance reflects external factors like market shaping, pricing, and country-level dynamics. It noted that it would provide more clarity at the October 2025 meeting.
- Regarding the currency hedging strategy, the Secretariat explained that Gavi has already commenced hedging based on relatively certain amounts.
- The Secretariat confirmed that equity accelerator disbursements extended into 2027 would draw from Gavi 6.0 resources and would be included in the recalibration framework.
- One Committee Member expressed interest in understanding the technical aspects of vaccine demand forecasting and suggested that it could be beneficial to have a technical briefing on this topic.
- The Committee agreed to the following guidance language:

  The Gavi Alliance Audit and Finance Committee is requested to **review** and **provide guidance** on the financial projections relating to Resources, Expenditure and Recalibration for the Gavi 6.0 strategic period (2026 -2030), and

  a) **Note** the range of available resources for the Gavi 6.0 strategic period (2026-2030) is projected to be US$ 9.5 billion – US$ 10.5 billion. Negotiations with donors are ongoing and it may take several months to make a firmer estimate, including of any potential upside. No estimate has been made for any amounts that could be raised later in the Gavi 6.0strategic period;

  b) **Note** the Gavi 6.0 Strategic Cost Estimate (US$ 11.9 billion approved by the Gavi Alliance Board in June 2024) has been updated to a recalibration baseline of US$ 13.0 billion to reflect new items recommended by the Programme and Policy Committee and still subject to Board approval AND external factors/assumption changes;

  c) **Note** that the Gavi 6.0 strategy will require recalibration discussions by the Gavi Board at its 22-23 July 2025 retreat, and that based on estimated available resources and the revised estimated expenditures, the recommended recalibration amounts are US$ 2.5 billion (to reach the higher recalibration target of US$ 10.5 billion) and US$ 3 billion (to reach a reasonable recalibration target of US$ 10 billion);

  d) **Note** the assumptions and principles for recalibration levers are reasonable; and

  e) **Note** the risks and opportunities to the financial projections of the Gavi 6.0 strategic period (2026-2030).

------

4. Any other business and review of decisions

4.1 After determining there was no further business, the meeting was brought to a close.

------

5. *Closed Session for members only*

5.1 Members of the Secretariat were recused from the meeting and the Committee proceeded with a closed session (see separate minutes).

Ms Melissa Wolfe
Secretary to the Meeting

Attachment A: Participants

Committee Members

- David Sidwell (Chair)
- Latifou Aboudou
- Sara Baiocco
- Lotta Sandö Brandt
- Carmen Coles
- Ana de Pro Gonzalo
- Lauren Franzel
- Gisela Henrique
- Kelly Jarrett
- Ashish Makkar
- Kwaku Agyeman Manu
- Sara Schulz
- Deena Shiff
- Karen Sørensen

Regrets

- Onei Uetela

Observers/Guests

- Lisa Watson, Deloitte
- Annik Jaton Hüni, Deloitte

Secretariat

- Johannes Ahrendts
- Andrea Antonelli
- Hannah Burris
- Lucy Elliott
- Quentin Guillon
- Nikoletta Gutyan
- Adviya Khan
- Brenda Killen
- David Kinder
- Niamh Lawless
- Ian MacTavish
- Sania Nishtar
- François Note
- Marie-Ange Saraka-Yao
- Marie Rochat
- Maria Thestrup
- Tobias Thiessen
- An Vermeesch